LATANGRA MCINTOSH: Open Payments
NPI 1831156298 · TAMPA, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,186 in 47 payments from 12 companies in 2025. Trend: 2023 $84 · 2024 $209 · 2025 $1,186
Food & beverage: $1,186
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 7 | $299 |
| Teva Pharmaceuticals USA, Inc. | 16 | $298 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $130 |
| Alkermes, Inc. | 4 | $85 |
| Lundbeck LLC | 3 | $83 |
| Luye Pharma (USA) Ltd. | 3 | $64 |
| Axsome Therapeutics, Inc. | 2 | $56 |
| Janssen Pharmaceuticals, Inc | 2 | $54 |
| Otsuka America Pharmaceutical, Inc. | 2 | $47 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $31 |
Products named: INGREZZA, AUSTEDO XR, REXULTI, CAPLYTA, UZEDY, ERZOFRI EXTENDED-RELEASE, Auvelity, INVEGA SUSTENNA.
Industry payments across FL — which companies pay providers there.
